ライフサイエンスコーパス: bleeding

1 events (155 with moderate and 80 with severe bleeding).

2 .3% (0.1% with moderate and 0.2% with severe bleeding).

3 nts (GUSTO classification moderate or severe bleeding).

4 uids, or a case with diarrhoea, vomiting, or bleeding).

5 at the coexistent coagulopathy could promote bleeding.

6 cted and assessed for consistency and occult bleeding.

7 (ITP) increased platelet counts and reduced bleeding.

8 ntracranial bleeding or other critical organ bleeding.

9 ion on experimental thrombus dissolution and bleeding.

10 systemic anticoagulation is difficult due to bleeding.

11 We also assessed variceal and nonvariceal bleeding.

12 sis In Myocardial Infarction major and minor bleeding.

13 ge or gastrointestinal, urogenital, or other bleeding.

14 cting the location of acute gastrointestinal bleeding.

15 defined a new HCA subgroup at a high risk of bleeding.

16 The primary safety end point was major bleeding.

17 d antithrombotic efficacy without increasing bleeding.

18 enesis, gastrointestinal angiodysplasia, and bleeding.

19 ts on NOACs who bleed or who are at risk for bleeding.

20 old but does not increase the risk of major bleeding.

21 vents after coronary stenting, but increases bleeding.

22 ic tumour excision to reduce intra-operative bleeding.

23 age, were used to estimate rates of total GI bleeding.

24 ant for predicting oral hygiene and gingival bleeding.

25 e segment with a history of painless vaginal bleeding.

26 , and the principal safety outcome was major bleeding.

27 t degrade fibrinogen or enhance experimental bleeding.

28 with suspected lower gastrointestinal tract bleeding.

29 s 4.3% for MI, 0.9% for stroke, and 5.0% for bleeding.

30 nor bleedings and less incidence of variceal bleeding.

31 ays and the primary safety outcome was major bleeding.

32 ial modifiable risk factor for perioperative bleeding.

33 s risk of thrombosis and the severity of the bleeding.

34 , blood transfusion, and hospitalization for bleeding.

35 y intervention without an increase in severe bleeding.

36 rsistent thrombocytopenia, skin lesions) and bleedings.

37 stroke (3.3% versus 2.2%), life-threatening bleeding (1.1% versus 1.1%), and major vascular complica

38 nfarction (2.9% versus 0.2%; P<0.001), major bleeding (14.0% versus 0.9%; P<0.001), blood transfusion

39 LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or hernia-related complica

40 sus 42.1%; hazard ratio, 1.11; P<0.001), and bleeding (23.1% versus 19.7%; hazard ratio, 1.18; P<0.00

41 by men (582 [67.3%]), and for intraoperative bleeding (544 [62.9%]).

42 Respiratory (14.7%), infections (12.8%), bleeding (7.6%), and peripheral vascular disease (4.3%)

43 lined, including mortality (3.57% to 2.15%), bleeding (9.56% to 5.08%), vascular complications (6.11%

44 hich was further classified as the result of bleeding, a cardiovascular cause, or another cause blind

45 For major bleeding, a tenecteplase-based regimen tended to be asso

46 a significantly greater risk of access-site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1

47 cation, which was a composite of access-site bleeding, access-site hematoma, retroperitoneal bleeding

48 isease, anemia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular complica

49 y was associated with more, and more severe, bleeding (adjusted cOR 2.54, 95% CI 2.05-3.16, p<0.0001)

50 e interval, 1.42-3.59; P=0.0006), but not of bleeding (adjusted hazard ratio, 0.99; 95% confidence in

51 emonstrated by the complete normalization of bleeding after a severe tail clip injury in these mice.

52 ncluded rates of VTE and clinically relevant bleeding after surgical procedures, stratified by Caprin

53 e hazard of death, myocardial infarction, or bleeding (AKIN 1: hazard ratio [HR], 1.53; confidence in

54 Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but

55 mic embolic events and significantly reduced bleeding and cardiovascular mortality.

56 evated hematocrit is associated with reduced bleeding and increased thrombosis risk in humans.

57 rations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short

58 Bivalirudin has been associated with reduced bleeding and mortality during primary percutaneous coron

59 Anticoagulant therapy-associated bleeding and pathological thrombosis pose serious risks

60 dentified 2 unrelated families in the BRIDGE Bleeding and Platelet Disorders (BPD) collection who car

61 ty, we affirm the tradeoff between increased bleeding and reduced myocardial infarctions with prolong

62 test the hypothesis that laropiprant limits bleeding and rescues the brain from ICH.

63 Knowledge about risk of bleeding and short-term thrombotic risk resides in many

64 onin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between

65 Strategies to reduce the daily risk of bleeding and thrombosis, and different thresholds for tr

66 ted to the hospital are at increased risk of bleeding and thrombosis.

67 ac failure in children but is complicated by bleeding and thrombosis.

68 ened and stiffened clots are associated with bleeding and thrombotic disorders.

69 Bleeding and vascular complications, using permeable nit

70 valves had a higher cumulative incidence of bleeding and, in some age groups, stroke than did recipi

71 oagulants, with no excess of major and minor bleedings and less incidence of variceal bleeding.

72 ) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization.

73 Age <5 years, bleeding, and high viral loads were poor prognostic indi

74 rtality, renal failure, atrial fibrillation, bleeding, and length of intensive care unit stay.

75 reported relative risks for thrombosis, any bleeding, and major bleeding with antiplatelet therapy c

76 reported incidence rates of thrombosis, any bleeding, and major bleeding without antiplatelet therap

77 ssociated with risk factors, histopathology, bleeding, and malignant transformation.

78 troke, intracranial hemorrhage, extracranial bleeding, and myocardial infarction identified from hosp

79 In patients with overt gastrointestinal bleeding, and negative findings on esophagogastroduodeno

80 nd point analyses of vascular complications, bleeding, and new pacemaker/defibrillator implantation d

81 TIPS volume of </= 20 TIPS/year, variceal bleeding, and nosocomial infections were independent ris

82 hs, artificial ventilation, intraventricular bleeding, and other perinatal adverse events.

83 reased risk of death, myocardial infarction, bleeding, and recurrent renal injury after discharge.

84 testinal bleeding, with all gastrointestinal bleeding as a secondary outcome.

85 s had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor.

86 tional Society of Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH BAT) confirmed significan

87 Development and use of bleeding assessment tools allows for improved stratifica

88 ificant differences in rates of hospitalized bleeding at any time point.

89 one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable spleen of at

90 With the exception of minor bleeding at the injection site in a few animals injected

91 effect of anticoagulant therapy on menstrual bleeding at the time of treatment initiation.

92 hose undergoing transfemoral PCI, whereas no bleeding benefit was observed for those treated with tra

93 and also had an indirect effect on gingival bleeding (beta = 0.011; P = 0.05).

94 ively associated with the extent of gingival bleeding (beta = 0.24; P = 0.01).

95 proportions of patients with major or minor bleeding between groups that did vs did not receive anti

96 tality and rates of reoperation, stroke, and bleeding between inverse-probability-weighted cohorts of

97 mia significantly exceeded the daily risk of bleeding beyond 30 days, supporting the use of intensifi

98 (1) To measure the incidence of bleeding (blood loss requiring transfusion or intracrani

99 ng aorta or aortic arch) with intraoperative bleeding (blood volume between 60 and 250 mL suctioned f

100 Safety outcomes included major bleeding, blood transfusion, and hospitalization for ble

101 inolytic therapy increased the risk of major bleeding by 1.27-8.82-times compared with accelerated in

102 nticoagulants reduce the risk of intraocular bleeding by approximately one-fifth compared with warfar

103 ria ohridella, the bacterial causal agent of bleeding canker disease Pseudomonas syringae pv aesculi,

104 istory predictors of leaf miner infestation, bleeding canker, or coinfection.

105 toma expansion was tested by an in vivo tail bleeding cessation method and an ex vivo coagulation met

106 sociated with increased incidence rate of GI bleeding compared with non-exposed period among naive da

107 n tended to be associated with lower risk of bleeding compared with other regimens (RR 0.79 [95% CI 0

108 ban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%]

109 d risk of all severities of gastrointestinal bleeding compared with warfarin (0.25 [0.07-0.76]) or da

110 nsplant recipient and resulted in death from bleeding complications 18 days posttransplantation.

111 Bleeding complications arising from trauma, surgery, and

112 e with heart failure signs at admission, and bleeding complications increased with higher MI-ERR.

113 Bleeding complications occurred in alternatively anticoa

114 and those with non-healing wounds or active bleeding conditions were ineligible.

115 ntary test in patients with gastrointestinal bleeding, Crohn's disease, or celiac disease, who have h

116 Major bleeding, defined as hospitalization or emergency depart

117 Upper gastrointestinal bleeding developed in 6.1% of patients in the pantoprazo

118 Bleeding differences were, in part, explained by the gre

119 ts and actively block FVIII activity, making bleeding difficult to control and prevent.

120 ay platelet syndrome (GPS), a rare recessive bleeding disorder characterized by platelets lacking alp

121 ciency of factor X (F10) in humans is a rare bleeding disorder with a heterogeneous phenotype and lim

122 d disease (VWD) is the most common inherited bleeding disorder, yet diagnosis and management remain c

123 or hepatitis C viral infection, and a known bleeding disorder.

124 ent in a subset of patients with undiagnosed bleeding disorders, and therefore may function as a clin

125 and therapeutics for affected patients with bleeding disorders.

126 d tool for the prediction of out-of-hospital bleeding during DAPT.

127 Obstetrics complications and excessive bleeding during delivery contributed to nearly 30% of th

128 of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regar

129 ffer the promise to improve the treatment of bleeding episodes in patients with inhibitor-complicated

130 llow-up, 21 patients had at least one severe bleeding event (WHO bleeding score >/=2).

131 The cumulative incidence of death after a bleeding event among the total randomized study populati

132 (95% CI, 0.19 to 0.30) for any hospitalized bleeding event and 0.15 (95% CI, 0.11 to 0.20) for moder

133 The annualized mortality rate after a bleeding event was 21.5 (95% CI, 15.4-29.1) per 100 pers

134 stroke), and 232 individuals (2.0%) had 235 bleeding events (155 with moderate and 80 with severe bl

135 , stent thrombosis, and ischemic stroke) and bleeding events (GUSTO classification moderate or severe

136 (1582 [50%] aged >/=75 years) had 405 first bleeding events (n=218 gastrointestinal, n=45 intracrani

137 The risk of recurrent ischemic and bleeding events after primary percutaneous coronary inte

138 GI bleeding events among patient aged 75 years or older tak

139 life-threatening bleeding or major or minor bleeding events in patients with ipsilateral stenosis in

140 f GI surgery does not significantly increase bleeding events in the month after surgery.

141 s; and apixaban, 12886 patients), 4770 major bleeding events occurred during 447037 person-quarters w

142 ine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were

143 claims-identified and physician-adjudicated bleeding events was poor, with a kappa of 0.24 (95% CI,

144 Fourteen patients (38%) experienced bleeding events, of which six (16%) were associated with

145 tive in raising platelet counts and reducing bleeding events.

146 Although the rates for bleeding exceeded those for ischemia within 30 days, the

147 d death, all-cause death, and post-procedure bleeding favored LAAC (HR: 0.20; p = 0.0022; HR: 0.45; p

148 ng microsphere used to reduce intraoperative bleeding for head and neck tumours.

149 comes, including mortality, readmission, and bleeding, for patients with PAD compared with those with

150 e 5: Patients at high risk for ulcer-related bleeding from NSAIDs should take a PPI if they continue

151 stimates of the association between gingival bleeding (GB) and oral health-related quality of life (O

152 h was associated with a higher risk of major bleeding (hazard ratio: 2.19; 95% confidence interval: 1

153 Therefore, stoppage of bleeding (hemostasis) is of paramount clinical significa

154 ation (ascites, encephalopathy, and variceal bleeding), hepatocellular carcinoma, liver transplantati

155 ignificantly more bleeders had a previous GI bleeding history before left ventricular assist device p

156 ts treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0.021) bu

157 nteraction [pint] = 0.26; and for less major bleeding, HR: 0.74; 95% CI: 0.53 to 1.02 in patients wit

158 s the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfront compli

159 d systemic infection in 11, gastrointestinal bleeding in 1, and severe electrolyte imbalance in 1, al

160 schemic attack in 1 patient, reoperation for bleeding in 2 patients, and median length of stay was 4

161 stem cells have been shown to control joint bleeding in animal models of hemophilia.

162 tatistically significant difference in major bleeding in apixaban-treated patients.

163 PI use was associated with increased risk of bleeding in both treatment arms.

164 longer DAPT duration significantly increased bleeding in patients at high risk (score >/=25), but not

165 Antifibrinolytics reduce death from bleeding in trauma and post-partum haemorrhage.

166 jor bleeding was unrelated to age, but major bleeding increased steeply with age (>/=75 years hazard

167 ollowing parameters were evaluated: gingival bleeding index (GBI), probing depth (PD), myeloperoxidas

168 and 9 months; they included modified sulcus bleeding index (mSBI), plaque index (PI), probing depth

169 included plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), and clinical

170 Plaque index, modified sulcus bleeding index, probing depth (PD), relative vertical at

171 primary end point was the composite of major bleeding, INR of 4 or greater, venous thromboembolism, o

172 Acute lower gastrointestinal bleeding is a common reason for emergency hospital admis

173 Acute upper gastrointestinal bleeding is a leading indication for red blood cell (RBC

174 Perioperative bleeding is a potentially devastating complication in ne

175 Gastrointestinal (GI) bleeding is one of the most common complications after c

176 Minor bleeding is the most common complication of dermatologic

177 re Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE]; NCT01623180).

178 ES improved their predictive value for major bleeding leading to improved clinical usefulness compare

179 the assessment of the effectiveness of major bleeding management.

180 the UHCA, of which 64.7% presented clinical bleeding manifestations.

181 use of postpancreatectomy sepsis (n = 11) or bleeding (n = 11).

182 myocardial infarction, and life-threatening bleeding occurred in 0.5%, 0.8%, and 4.0% of patients, r

183 Major bleeding occurred in 36 patients (6.9%) in the edoxaban

184 Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivar

185 GI bleeding occurred more frequently in patients given riva

186 ndex for out-of-hospital TIMI major or minor bleeding of 0.73 (95% CI 0.61-0.85) in the derivation co

187 ontal outcomes were percentage of teeth with bleeding on probing (BOP) and combination of BOP and att

188 were plaque index (PI), gingival index (GI), bleeding on probing (BOP), PD, gingival crevicular fluid

189 s of > 2 mm, probing depth (PD) >/=5 mm with bleeding on probing (BOP).

190 PD], plaque index [PI], gingival index [GI], bleeding on probing [BOP], and clinical attachment level

191 t soft tissue parameters (plaque index [PI], bleeding on probing [BOP], and probing depth [PD] >/=4 m

192 95% CI, 0.11 to 0.20) for moderate or severe bleeding on the GUSTO scale.

193 HPR was an independent predictor of reduced bleeding only in women (women: adjusted HR, 0.58; 95% CI

194 TIPS) correlates with the absence of further bleeding or ascites at follow-up examinations of patient

195 marrow hematopoiesis and EMH in response to bleeding or G-CSF treatment.

196 included IVF- and LD-related safety, such as bleeding or infections, and functional outcome at 90 and

197 rences in the proportion of life-threatening bleeding or major or minor bleeding events in patients w

198 was no significant increase in intracranial bleeding or other critical organ bleeding.

199 rom 2042 cases in pedigrees with unexplained bleeding or platelet disorders to data from 5422 control

200 The first 3 months after a major bleeding or surgical procedure were excluded from the ti

201 8-1.72; P=0.06), with no difference in major bleeding (OR, 1.47; 95% CI, 0.39-5.63; P=0.57) with MV-P

202 5) and weak evidence of an increase in major bleeding (OR, 1.66; 95% credible intervals, 0.89-3.09) a

203 eding, access-site hematoma, retroperitoneal bleeding, or any vascular complication requiring interve

204 vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome.

205 f 4 weeks: platelet transfusion, symptomatic bleeding, or platelet count of less than 10 x 10(9) per

206 combining proportion of teeth with calculus, bleeding, or pocket with income; number of lost teeth; s

207 We did not detect an increased risk of GI bleeding over dabigatran vs warfarin risk period.

208 02), vascular complications (p < 0.003), and bleeding (p < 0.001) but was not associated with stroke

209 xamic acid, with no heterogeneity by site of bleeding (p=0.5956).

210 TRUS-biopsy can cause side-effects including bleeding, pain, and infection.

211 arfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mortality

212 ed importance in diagnosing gastrointestinal bleeding, particularly in hemodynamically unstable patie

213 ive PFD associated with a moderate or severe bleeding phenotype and complex defects in platelet aggre

214 ssment Tool (ISTH BAT) confirmed significant bleeding phenotypes in the majority of LoVIC patients.

215 = 0.81), as was increase in moderate/severe bleeding (pinteraction = 0.44).

216 ed ligand binding-site antagonist results in bleeding, possibly owing to the important role of PAR1 a

217 Calculus, pocket, or bleeding presence at age 24 years separately presented f

218 non-steroidal anti-inflammatory drug (NSAID) bleeding prophylaxis.

219 and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perfora

220 A trend toward an increased bleeding rate at presentation was observed in HHT (p = 0

221 articipants, 28 to 78 weeks), the annualized bleeding rate was significantly reduced (mean rate, 11.1

222 h kidney disease had higher gastrointestinal bleeding rates with dabigatran.

223 use was associated with substantially higher bleeding rates, regardless of the randomization to cangr

224 ved octreotide, to provide a context for the bleeding rates.

225 a platelet transfusion at the first sign of bleeding, rather than prophylactically.

226 revious admission for lower gastrointestinal bleeding, rectal examination findings, heart rate, systo

227 nt factor 3 (C3) deficiency causes prolonged bleeding, reduced thrombus incidence, thrombus size, fib

228 cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss.

229 Before GPI adjustment, bleeding reductions with bivalirudin ranged from 2.04% (

230 coagulation to devise whole-body fasting and bleeding regimens to prevent rupture.

231 rently identified by default, a high risk of bleeding remains a clinical issue.

232 Bleeding remains a significant problem for many thromboc

233 me (disability or death), and time course of bleeding requiring medical attention by face-to-face fol

234 associated with malignant transformation and bleeding, respectively.

235 the benefit of anticoagulation outweighs the bleeding risk (net clinical benefit) has been shown to b

236 Uncertainty remains as to which markers of bleeding risk are independent predictors.

237 Guidelines support weighting bleeding risk before the selection of treatment duration

238 imilar ischemic risk and lower risk-adjusted bleeding risk compared with clopidogrel-GPIs.

239 over BMS were maintained for 2 years in high bleeding risk patients.

240 ratified by trial, and developed a numerical bleeding risk score.

241 Bleeding risk with vitamin K antagonists (VKAs) is close

242 ents with severe kidney disease may increase bleeding risk, whereas dose reductions without a firm in

243 ivator) therapy may be required, despite its bleeding risk.

244 -6 months) treatment in relation to baseline bleeding risk.

245 risk of MI but was associated with increased bleeding risk.

246 To compare the ischemic and bleeding risks associated with glycoprotein IIb/IIIa inh

247 Safety was assessed by 3 validated bleeding scales (Global Use of Strategies to Open Occlud

248 had at least one severe bleeding event (WHO bleeding score >/=2).

249 ween each HL measure versus number of teeth, bleeding score, plaque score, and periodontal severity w

250 e-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI majo

251 atients with cirrhosis and previous variceal bleeding stratified by cirrhosis severity (Child A versu

252 Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical

253 sis to reduce the frequent adverse events of bleeding, stroke, and pump thrombosis; and they must bec

254 device implantation with no deaths, strokes, bleeding, tamponade, or valve reintervention.

255 d with peptic ulcer disease and an increased bleeding tendency.

256 For major bleeding, the addition of vWF to HAS-BLED improved the c

257 crease in the risk of upper gastrointestinal bleeding; the effect of proton pump inhibitors on ventil

258 studies (257 patients) reported rates of any bleeding; there was no difference in the proportions of

259 rce and the cause of active gastrointestinal bleeding, thereby expediting treatment initiation.

260 For "any bleeding," this was lower for treatment with apixaban an

261 on of HRAE (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neur

262 ve shown that platelets prevent inflammatory bleeding through (hem) immunoreceptor tyrosine-based act

263 Tail bleeding time was prolonged in DREAM KO control mice, bu

264 The tail bleeding time was significantly lower in laropiprant gro

265 lasma and activity levels as well as reduced bleeding times, indicating that mast cells are more effi

266 in those patients with perforation including bleeding, transfusion, myocardial infarction, and death.

267 Upper gastrointestinal bleeding (UGIB) is a common gastrointestinal emergency,

268 deleterious effect on the extent of gingival bleeding via a worse oral hygiene status of children, bu

269 Vascular and bleeding volume-outcome associations were nonlinear with

270 e effect of cangrelor on ischemic events and bleeding was analyzed in the subgroup of patients with a

271 Bleeding was associated with higher mortality (adjusted

272 m any cause, myocardial infarction, or major bleeding was not lower among those who received bivaliru

273 Bleeding was rare at presentation (5%) and manifested su

274 No major bleeding was recorded, and no patient died during the st

275 ders, the incidence rate of gastrointestinal bleeding was similar during dabigatran risk period and n

276 Risk of non-major bleeding was unrelated to age, but major bleeding increa

277 In all patients, bleeding was verified by means of other methods such as

278 death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years 1, 2,

279 (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and rand

280 nt admissions for ischemic strokes and major bleeding were compared across the 3 drugs (rivaroxaban:

281 revascularization (RR); and (4) hospitalized bleeding were compared using Cox proportional hazards re

282 Reductions in bleeding were largest among those undergoing transfemora

283 Data on intraocular bleeding were pooled using inverse-variance, weighted, f

284 ed with thrombosis but result in less severe bleeding when co-inherited with hemophilia.

285 gnificantly increased the risk for any major bleeding when compared with warfarin (hazard ratio, 1.20

286 associated with a similar risk of any major bleeding when compared with warfarin and dabigatran.

287 year after MI were lower for MI, stroke, and bleeding when medical claims were used to identify event

288 ents) reported rates of spontaneous variceal bleeding, which occurred in a significantly lower propor

289 dentify patients with lower gastrointestinal bleeding who are suitable for safe outpatient management

290 dentify patients with lower gastrointestinal bleeding who could safely avoid hospital admission.

291 isks for thrombosis, any bleeding, and major bleeding with antiplatelet therapy compared with none ra

292 tes of GUSTO-defined severe/life-threatening bleeding with cangrelor alone compared with clopidogrel-

293 nificant difference in GUSTO moderate/severe bleeding with cangrelor versus clopidogrel (1.1% versus

294 o increase in risk of major gastrointestinal bleeding with direct oral anticoagulants compared with w

295 To characterize the risk of intraocular bleeding with novel oral anticoagulants compared with wa

296 It is unclear if the risk of intraocular bleeding with novel oral anticoagulants differs compared

297 Comparably lower risks of intraocular bleeding with novel oral anticoagulants were seen in sub

298 was the incidence of major gastrointestinal bleeding, with all gastrointestinal bleeding as a second

299 symptomatic venous thromboembolism and major bleeding within 3 months after the procedure.

300 rates of thrombosis, any bleeding, and major bleeding without antiplatelet therapy ranged from 5 to 1